Statin Use is Associated with Improved Outcomes of Patients With Primary Sclerosing Cholangitis

Abstract Background & Aims There is increasing evidence that statins can benefit patients with chronic liver diseases, but their effects have not been studied in patients with primary sclerosing cholangitis (PSC). We performed a nationwide study in Sweden to determine the effects of exposure to drugs, including statins, in patients with PSC. Methods We studied a population-based cohort of patients in Sweden with PSC and concomitant ulcerative colitis or Crohn´s disease from 2005 through 2014 (n=2914), followed through 2016. We collected analyzed data from the patient register, the prescribed drug register, the death certificate register and the cancer register. We calculated risk or death, liver transplantation, bleeding of esophageal varices, and cancer in relation to drug exposure. Results The mean age of patients at the time of diagnosis with PSC was 41.4 years (inter-quartile range [IQR], 25.6–56.1 years). The total follow-up time was 11769 person-years, during which 3.4% of patients received liver transplants and 19.9% died. Proportions of patients exposed to drugs were: ursodeoxycholic acid, 60.2%; 5-aminosalicylic acid, 74.4%; azathioprine or mercaptopurins, 33.7%; and statins, 13.9%. Statin use was associated with a reduced risk of all-cause mortality (hazard ratio [HR], 0.68; 95% CI, 0.54–0.88) and death or liver transplantation (HR, 0.50; 95% CI, 0.28–0.66). Use of azathioprine was also associated with reduced mortality (HR, 0.66; 95% CI, 0.52–0.84) and risk of death or liver transplantation (HR, 0.65; 95% CI, 0.50–0.83). Exposure to ursodeoxycholic acid did not affect mortality (HR, 1.04; 95% CI, 0.87–1.25). Conclusion In a population-based cohort of patients in Sweden with PSC, we associated use of statins and azathioprine with decreased risks of death and death or liver transplantation. Exposure to ursodeoxycholic acid was not associated with reduced mortality.